Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Toxoplasma | 61 | 2021 | 108 | 11.780 |
Why?
|
Toxoplasmosis | 31 | 2021 | 64 | 8.000 |
Why?
|
Toxoplasmosis, Congenital | 24 | 2021 | 42 | 4.380 |
Why?
|
Toxoplasmosis, Animal | 14 | 2019 | 19 | 2.790 |
Why?
|
Antiprotozoal Agents | 15 | 2013 | 33 | 2.550 |
Why?
|
Enoyl-(Acyl-Carrier-Protein) Reductase (NADH) | 11 | 2013 | 12 | 1.940 |
Why?
|
Protozoan Vaccines | 5 | 2016 | 11 | 1.930 |
Why?
|
Protozoan Proteins | 12 | 2018 | 73 | 1.920 |
Why?
|
Antibodies, Protozoan | 12 | 2021 | 34 | 1.920 |
Why?
|
Toxoplasmosis, Ocular | 10 | 2018 | 17 | 1.680 |
Why?
|
Triclosan | 9 | 2013 | 10 | 1.470 |
Why?
|
Epitopes, T-Lymphocyte | 5 | 2016 | 89 | 1.380 |
Why?
|
Coccidiostats | 4 | 2013 | 4 | 1.370 |
Why?
|
Plasmodium falciparum | 11 | 2020 | 47 | 1.170 |
Why?
|
Pregnancy Complications, Parasitic | 7 | 2018 | 15 | 1.130 |
Why?
|
Antigens, Protozoan | 8 | 2020 | 21 | 0.960 |
Why?
|
CD8-Positive T-Lymphocytes | 7 | 2020 | 556 | 0.920 |
Why?
|
Immunoglobulin M | 6 | 2021 | 154 | 0.880 |
Why?
|
Spiramycin | 2 | 2021 | 2 | 0.860 |
Why?
|
Neglected Diseases | 1 | 2021 | 1 | 0.850 |
Why?
|
Animals | 57 | 2020 | 26518 | 0.850 |
Why?
|
Observational Studies as Topic | 1 | 2021 | 48 | 0.820 |
Why?
|
Mice | 30 | 2020 | 11313 | 0.790 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2021 | 105 | 0.780 |
Why?
|
Parasites | 1 | 2020 | 8 | 0.760 |
Why?
|
Interferon-gamma | 6 | 2014 | 444 | 0.690 |
Why?
|
Hydrocephalus | 2 | 2015 | 101 | 0.660 |
Why?
|
Genotype | 7 | 2018 | 1850 | 0.640 |
Why?
|
Mice, Transgenic | 10 | 2020 | 1537 | 0.640 |
Why?
|
Female | 54 | 2021 | 44405 | 0.630 |
Why?
|
Oocysts | 4 | 2017 | 7 | 0.630 |
Why?
|
HLA-A Antigens | 3 | 2016 | 44 | 0.630 |
Why?
|
Cytokines | 4 | 2018 | 775 | 0.620 |
Why?
|
Pregnancy | 15 | 2021 | 2885 | 0.620 |
Why?
|
Pets | 1 | 2017 | 8 | 0.610 |
Why?
|
Cat Diseases | 1 | 2017 | 20 | 0.610 |
Why?
|
Dog Diseases | 1 | 2017 | 35 | 0.600 |
Why?
|
HLA-B7 Antigen | 3 | 2020 | 7 | 0.590 |
Why?
|
Triazines | 2 | 2008 | 47 | 0.570 |
Why?
|
Adjuvants, Immunologic | 4 | 2020 | 166 | 0.570 |
Why?
|
Quinolones | 1 | 2016 | 60 | 0.560 |
Why?
|
Toxoplasmosis, Cerebral | 3 | 2009 | 6 | 0.550 |
Why?
|
Antiparasitic Agents | 3 | 2013 | 8 | 0.550 |
Why?
|
Oxidoreductases | 4 | 2004 | 111 | 0.540 |
Why?
|
Antimalarials | 5 | 2012 | 20 | 0.540 |
Why?
|
Encephalitis | 2 | 2008 | 104 | 0.540 |
Why?
|
Drug Discovery | 1 | 2016 | 103 | 0.530 |
Why?
|
Humans | 77 | 2021 | 86281 | 0.530 |
Why?
|
Nervous System Diseases | 1 | 2016 | 151 | 0.530 |
Why?
|
Family Health | 1 | 2015 | 162 | 0.530 |
Why?
|
Immunoglobulin G | 7 | 2021 | 456 | 0.520 |
Why?
|
Models, Molecular | 10 | 2018 | 1284 | 0.510 |
Why?
|
Fathers | 1 | 2015 | 68 | 0.510 |
Why?
|
Drug Design | 4 | 2013 | 124 | 0.510 |
Why?
|
Sulfadiazine | 7 | 2008 | 24 | 0.510 |
Why?
|
Cells, Cultured | 10 | 2020 | 2810 | 0.500 |
Why?
|
Cluster Analysis | 1 | 2015 | 369 | 0.500 |
Why?
|
Benzamides | 2 | 2012 | 226 | 0.490 |
Why?
|
Mice, Inbred C57BL | 11 | 2016 | 3087 | 0.490 |
Why?
|
Autoimmune Diseases | 1 | 2016 | 241 | 0.490 |
Why?
|
Nanoparticles | 2 | 2020 | 157 | 0.480 |
Why?
|
Spiro Compounds | 1 | 2013 | 25 | 0.480 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 4 | 2017 | 376 | 0.460 |
Why?
|
Proctocolectomy, Restorative | 2 | 2006 | 87 | 0.450 |
Why?
|
Genes, MHC Class I | 4 | 2010 | 48 | 0.450 |
Why?
|
Infant | 17 | 2021 | 3036 | 0.450 |
Why?
|
Salicylanilides | 1 | 2012 | 1 | 0.450 |
Why?
|
Morpholinos | 1 | 2012 | 13 | 0.440 |
Why?
|
Fibroblasts | 7 | 2013 | 729 | 0.440 |
Why?
|
Genetic Predisposition to Disease | 4 | 2018 | 2267 | 0.430 |
Why?
|
Promoter Regions, Genetic | 2 | 2018 | 937 | 0.430 |
Why?
|
Chorioretinitis | 3 | 2008 | 10 | 0.430 |
Why?
|
Mice, Inbred BALB C | 7 | 2014 | 1047 | 0.420 |
Why?
|
Adaptor Proteins, Vesicular Transport | 1 | 2012 | 49 | 0.420 |
Why?
|
Parasitology | 1 | 2011 | 2 | 0.420 |
Why?
|
Indoles | 1 | 2013 | 318 | 0.420 |
Why?
|
Vaccines, Subunit | 3 | 2020 | 55 | 0.410 |
Why?
|
Peptides | 2 | 2014 | 639 | 0.410 |
Why?
|
H-2 Antigens | 3 | 2010 | 58 | 0.410 |
Why?
|
Polymorphism, Single Nucleotide | 5 | 2018 | 2350 | 0.400 |
Why?
|
Phenyl Ethers | 1 | 2010 | 13 | 0.390 |
Why?
|
Amino Acid Sequence | 10 | 2011 | 2062 | 0.380 |
Why?
|
Ribosomal Proteins | 1 | 2010 | 43 | 0.380 |
Why?
|
Disease Models, Animal | 7 | 2016 | 2227 | 0.380 |
Why?
|
Infant, Newborn | 11 | 2015 | 2369 | 0.380 |
Why?
|
Genetic Therapy | 1 | 2012 | 342 | 0.370 |
Why?
|
Structure-Activity Relationship | 6 | 2013 | 408 | 0.370 |
Why?
|
Enzyme Inhibitors | 7 | 2013 | 632 | 0.370 |
Why?
|
Nitriles | 1 | 2010 | 145 | 0.370 |
Why?
|
Pyridines | 2 | 2010 | 309 | 0.370 |
Why?
|
Carrier Proteins | 2 | 2013 | 672 | 0.360 |
Why?
|
Point-of-Care Testing | 2 | 2021 | 24 | 0.360 |
Why?
|
Child, Preschool | 16 | 2016 | 3608 | 0.360 |
Why?
|
Prevalence | 5 | 2021 | 1239 | 0.350 |
Why?
|
Cats | 4 | 2017 | 303 | 0.350 |
Why?
|
Molecular Sequence Data | 11 | 2011 | 3029 | 0.340 |
Why?
|
Cell Proliferation | 3 | 2013 | 1571 | 0.340 |
Why?
|
Cell Cycle | 1 | 2010 | 502 | 0.330 |
Why?
|
Nerve Degeneration | 1 | 2008 | 83 | 0.330 |
Why?
|
Child | 19 | 2016 | 6913 | 0.330 |
Why?
|
Apicomplexa | 2 | 2012 | 5 | 0.330 |
Why?
|
Infectious Disease Transmission, Vertical | 5 | 2010 | 44 | 0.320 |
Why?
|
Cryptosporidium parvum | 2 | 2005 | 4 | 0.310 |
Why?
|
HIV Infections | 1 | 2016 | 768 | 0.310 |
Why?
|
Crohn Disease | 4 | 2001 | 729 | 0.300 |
Why?
|
Mass Screening | 1 | 2011 | 615 | 0.300 |
Why?
|
Agglutination Tests | 2 | 2017 | 11 | 0.290 |
Why?
|
Shikimic Acid | 2 | 2006 | 2 | 0.290 |
Why?
|
Male | 33 | 2021 | 40860 | 0.280 |
Why?
|
Genes, MHC Class II | 3 | 2002 | 30 | 0.280 |
Why?
|
Drug Hypersensitivity | 1 | 2006 | 37 | 0.280 |
Why?
|
Brain | 6 | 2011 | 2211 | 0.280 |
Why?
|
Molecular Structure | 5 | 2013 | 287 | 0.280 |
Why?
|
Colonic Pouches | 1 | 2006 | 67 | 0.270 |
Why?
|
Cohort Studies | 7 | 2015 | 2759 | 0.270 |
Why?
|
Serologic Tests | 2 | 2018 | 41 | 0.270 |
Why?
|
Pyrimethamine | 7 | 2008 | 21 | 0.260 |
Why?
|
Adolescent | 16 | 2021 | 8968 | 0.260 |
Why?
|
Microbial Sensitivity Tests | 4 | 2013 | 142 | 0.260 |
Why?
|
Tetrahydrofolate Dehydrogenase | 3 | 2012 | 32 | 0.260 |
Why?
|
Anastomosis, Surgical | 1 | 2006 | 264 | 0.260 |
Why?
|
Epitopes | 2 | 2020 | 255 | 0.260 |
Why?
|
United States | 9 | 2018 | 6637 | 0.250 |
Why?
|
Incidence | 5 | 2016 | 1568 | 0.250 |
Why?
|
Monocytes | 3 | 2016 | 214 | 0.240 |
Why?
|
Drug Resistance | 2 | 2016 | 256 | 0.240 |
Why?
|
Mitochondria | 2 | 2005 | 535 | 0.240 |
Why?
|
Alleles | 3 | 2018 | 1127 | 0.230 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2020 | 425 | 0.220 |
Why?
|
Cell Line | 9 | 2016 | 2466 | 0.210 |
Why?
|
Recurrence | 7 | 2011 | 1137 | 0.210 |
Why?
|
Bone Neoplasms | 4 | 2000 | 322 | 0.210 |
Why?
|
Glycine | 1 | 2002 | 90 | 0.210 |
Why?
|
Colombia | 2 | 2018 | 11 | 0.210 |
Why?
|
Pupil Disorders | 1 | 2021 | 1 | 0.200 |
Why?
|
Seroepidemiologic Studies | 2 | 2021 | 55 | 0.200 |
Why?
|
Megalencephaly | 1 | 2021 | 21 | 0.200 |
Why?
|
Pouchitis | 1 | 2001 | 44 | 0.200 |
Why?
|
Adult | 24 | 2021 | 25577 | 0.190 |
Why?
|
In Vitro Techniques | 2 | 2013 | 987 | 0.190 |
Why?
|
Morbidity | 2 | 2016 | 146 | 0.190 |
Why?
|
Risk Factors | 7 | 2021 | 5397 | 0.180 |
Why?
|
Nitric Oxide | 2 | 2010 | 277 | 0.180 |
Why?
|
Sequence Alignment | 4 | 2007 | 351 | 0.180 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2000 | 109 | 0.180 |
Why?
|
Virulence | 3 | 2015 | 270 | 0.180 |
Why?
|
Neurons | 1 | 2008 | 1545 | 0.180 |
Why?
|
Soft Tissue Neoplasms | 1 | 2000 | 126 | 0.180 |
Why?
|
Disease Susceptibility | 2 | 2018 | 192 | 0.180 |
Why?
|
Gene Frequency | 2 | 2018 | 676 | 0.180 |
Why?
|
One Health | 1 | 2019 | 2 | 0.180 |
Why?
|
Nitric Oxide Synthase | 1 | 2000 | 125 | 0.180 |
Why?
|
HLA-DQ Antigens | 1 | 1999 | 52 | 0.180 |
Why?
|
Immunoassay | 2 | 2017 | 92 | 0.170 |
Why?
|
Vaccination | 2 | 2011 | 253 | 0.170 |
Why?
|
Collagen Type II | 2 | 2009 | 14 | 0.170 |
Why?
|
Vaccines | 1 | 2000 | 78 | 0.170 |
Why?
|
Inhibitory Concentration 50 | 3 | 2013 | 64 | 0.170 |
Why?
|
Sarcoma | 1 | 2000 | 211 | 0.170 |
Why?
|
Crystallography, X-Ray | 4 | 2018 | 484 | 0.170 |
Why?
|
Radiotherapy | 1 | 2000 | 326 | 0.160 |
Why?
|
Enzymes | 1 | 2018 | 47 | 0.160 |
Why?
|
Spleen | 2 | 2014 | 430 | 0.160 |
Why?
|
Drug Delivery Systems | 2 | 2013 | 178 | 0.160 |
Why?
|
ATP-Binding Cassette Transporters | 2 | 2009 | 141 | 0.160 |
Why?
|
Gene Knockdown Techniques | 3 | 2018 | 234 | 0.160 |
Why?
|
T-Lymphocytes, Cytotoxic | 3 | 2010 | 314 | 0.160 |
Why?
|
Panama | 1 | 2017 | 2 | 0.150 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2013 | 1958 | 0.150 |
Why?
|
Lymphadenitis | 1 | 1996 | 6 | 0.150 |
Why?
|
Age Factors | 3 | 2008 | 1842 | 0.150 |
Why?
|
Chicago | 2 | 2015 | 1377 | 0.150 |
Why?
|
Fertilization | 1 | 1996 | 40 | 0.150 |
Why?
|
Parasite Egg Count | 1 | 2016 | 6 | 0.150 |
Why?
|
HLA-A2 Antigen | 2 | 2020 | 31 | 0.150 |
Why?
|
Cytochromes b | 1 | 2016 | 9 | 0.150 |
Why?
|
Chickens | 1 | 2017 | 212 | 0.150 |
Why?
|
Mice, Inbred C3H | 3 | 2002 | 370 | 0.150 |
Why?
|
Case-Control Studies | 2 | 2018 | 1801 | 0.150 |
Why?
|
Principal Component Analysis | 1 | 2017 | 155 | 0.140 |
Why?
|
Cross-Priming | 1 | 2016 | 48 | 0.140 |
Why?
|
Anti-Bacterial Agents | 1 | 2021 | 739 | 0.140 |
Why?
|
Animal Welfare | 1 | 2017 | 41 | 0.140 |
Why?
|
Chronic Disease | 3 | 2008 | 968 | 0.140 |
Why?
|
Parasitic Diseases, Animal | 1 | 1995 | 1 | 0.140 |
Why?
|
Sheep Diseases | 1 | 1995 | 2 | 0.140 |
Why?
|
Dogs | 1 | 2017 | 684 | 0.140 |
Why?
|
Animals, Domestic | 1 | 1995 | 12 | 0.140 |
Why?
|
Cattle Diseases | 1 | 1995 | 7 | 0.140 |
Why?
|
Serogroup | 1 | 2015 | 9 | 0.140 |
Why?
|
International Classification of Diseases | 1 | 2016 | 69 | 0.140 |
Why?
|
Morocco | 3 | 2021 | 16 | 0.140 |
Why?
|
Drug Administration Schedule | 2 | 2009 | 916 | 0.140 |
Why?
|
Haplotypes | 1 | 2018 | 642 | 0.140 |
Why?
|
Urban Population | 1 | 2017 | 213 | 0.140 |
Why?
|
Animal Husbandry | 1 | 1995 | 25 | 0.140 |
Why?
|
Aminosalicylic Acids | 1 | 1995 | 42 | 0.130 |
Why?
|
Luminescent Proteins | 2 | 2013 | 144 | 0.130 |
Why?
|
Immunologic Memory | 1 | 2016 | 152 | 0.130 |
Why?
|
Gene Regulatory Networks | 1 | 2018 | 291 | 0.130 |
Why?
|
Bacterial Translocation | 1 | 2015 | 25 | 0.130 |
Why?
|
Salmonella Infections, Animal | 1 | 2015 | 10 | 0.130 |
Why?
|
Sequence Homology, Amino Acid | 2 | 2008 | 416 | 0.130 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2015 | 37 | 0.130 |
Why?
|
Salmonella typhimurium | 1 | 2015 | 31 | 0.130 |
Why?
|
Polymerase Chain Reaction | 5 | 2017 | 927 | 0.130 |
Why?
|
Apolipoproteins A | 1 | 1994 | 11 | 0.130 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2016 | 203 | 0.130 |
Why?
|
Feces | 1 | 2016 | 316 | 0.130 |
Why?
|
Intestinal Mucosa | 2 | 2015 | 788 | 0.130 |
Why?
|
Parasitic Sensitivity Tests | 3 | 2013 | 5 | 0.130 |
Why?
|
Endoscopy | 1 | 1997 | 331 | 0.120 |
Why?
|
Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 101 | 0.120 |
Why?
|
Genes, Protozoan | 2 | 2004 | 9 | 0.120 |
Why?
|
Apolipoproteins B | 1 | 1994 | 38 | 0.120 |
Why?
|
Apolipoprotein A-I | 1 | 1994 | 71 | 0.120 |
Why?
|
Protein Precursors | 1 | 1994 | 143 | 0.120 |
Why?
|
Arachidonate 12-Lipoxygenase | 1 | 2014 | 23 | 0.120 |
Why?
|
Drug Therapy, Combination | 5 | 2008 | 893 | 0.120 |
Why?
|
Mitochondrial Proteins | 2 | 2005 | 123 | 0.120 |
Why?
|
Sequence Deletion | 1 | 1994 | 205 | 0.110 |
Why?
|
Visual Acuity | 4 | 2008 | 194 | 0.110 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 1995 | 241 | 0.110 |
Why?
|
Interleukin-1 Receptor-Associated Kinases | 1 | 2012 | 7 | 0.110 |
Why?
|
Adenosine Triphosphatases | 1 | 2013 | 153 | 0.110 |
Why?
|
Lymphocytes | 1 | 2015 | 461 | 0.110 |
Why?
|
Endoplasmic Reticulum | 1 | 1994 | 250 | 0.110 |
Why?
|
Benzimidazoles | 1 | 2013 | 140 | 0.110 |
Why?
|
Middle Aged | 10 | 2021 | 24957 | 0.110 |
Why?
|
Zebrafish | 1 | 2015 | 307 | 0.110 |
Why?
|
Binding Sites | 2 | 2013 | 1098 | 0.110 |
Why?
|
Comorbidity | 1 | 2016 | 943 | 0.110 |
Why?
|
Trypanocidal Agents | 1 | 2012 | 2 | 0.110 |
Why?
|
Serotyping | 1 | 2012 | 28 | 0.110 |
Why?
|
Leishmania donovani | 1 | 2012 | 2 | 0.110 |
Why?
|
Trypanosoma | 1 | 2012 | 3 | 0.110 |
Why?
|
Immunity, Innate | 4 | 2015 | 405 | 0.110 |
Why?
|
Quantitative Structure-Activity Relationship | 1 | 2012 | 8 | 0.110 |
Why?
|
Luciferases | 1 | 2012 | 118 | 0.110 |
Why?
|
Imides | 1 | 2012 | 26 | 0.110 |
Why?
|
Blotting, Western | 2 | 2011 | 781 | 0.110 |
Why?
|
HLA-A1 Antigen | 1 | 2011 | 1 | 0.110 |
Why?
|
Prenatal Diagnosis | 2 | 2005 | 104 | 0.110 |
Why?
|
Secretory Pathway | 1 | 2012 | 22 | 0.110 |
Why?
|
Lymphocyte Activation | 3 | 2020 | 727 | 0.110 |
Why?
|
Cricetinae | 2 | 2008 | 560 | 0.100 |
Why?
|
Gene Transfer Techniques | 1 | 2012 | 152 | 0.100 |
Why?
|
Recombinant Proteins | 3 | 2013 | 1014 | 0.100 |
Why?
|
Ileostomy | 1 | 1991 | 30 | 0.100 |
Why?
|
Severity of Illness Index | 2 | 2009 | 1796 | 0.100 |
Why?
|
Food Contamination | 1 | 2011 | 31 | 0.100 |
Why?
|
Treatment Outcome | 6 | 2008 | 7949 | 0.100 |
Why?
|
Organelles | 1 | 2012 | 52 | 0.100 |
Why?
|
Bacterial Proteins | 3 | 2013 | 861 | 0.100 |
Why?
|
Gene Expression Regulation | 4 | 2010 | 1917 | 0.100 |
Why?
|
RNA, Messenger | 2 | 2012 | 1975 | 0.100 |
Why?
|
Myosin Subfragments | 1 | 2011 | 6 | 0.100 |
Why?
|
Models, Economic | 1 | 2011 | 60 | 0.100 |
Why?
|
Myosin Light Chains | 1 | 2011 | 29 | 0.100 |
Why?
|
Protein Binding | 2 | 2016 | 1454 | 0.100 |
Why?
|
Tetracyclines | 1 | 2010 | 4 | 0.100 |
Why?
|
Ileum | 1 | 2011 | 158 | 0.100 |
Why?
|
Enzyme Activation | 2 | 2013 | 692 | 0.100 |
Why?
|
Cataract | 2 | 2011 | 85 | 0.100 |
Why?
|
Nitrobenzenes | 1 | 2010 | 11 | 0.100 |
Why?
|
Cytochrome P-450 Enzyme Inhibitors | 1 | 2010 | 10 | 0.100 |
Why?
|
Epithelial Cells | 1 | 2015 | 662 | 0.100 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2011 | 132 | 0.100 |
Why?
|
Microsomes, Liver | 1 | 2010 | 49 | 0.100 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 1990 | 95 | 0.100 |
Why?
|
Eating | 1 | 2011 | 166 | 0.100 |
Why?
|
Small Molecule Libraries | 1 | 2011 | 61 | 0.100 |
Why?
|
Young Adult | 3 | 2021 | 5961 | 0.100 |
Why?
|
Colitis, Ulcerative | 2 | 2001 | 708 | 0.100 |
Why?
|
Receptors, Purinergic P2 | 1 | 2010 | 14 | 0.090 |
Why?
|
Aged | 7 | 2021 | 18353 | 0.090 |
Why?
|
Protein Transport | 1 | 2012 | 410 | 0.090 |
Why?
|
Immunization | 1 | 2010 | 158 | 0.090 |
Why?
|
Sensitivity and Specificity | 3 | 2021 | 1987 | 0.090 |
Why?
|
Retinal Diseases | 2 | 2011 | 90 | 0.090 |
Why?
|
HLA-B Antigens | 1 | 2010 | 35 | 0.090 |
Why?
|
Protein Biosynthesis | 1 | 2012 | 378 | 0.090 |
Why?
|
Vision Disorders | 2 | 2011 | 75 | 0.090 |
Why?
|
Lipopeptides | 1 | 2010 | 16 | 0.090 |
Why?
|
Aminopeptidases | 1 | 2010 | 17 | 0.090 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2010 | 39 | 0.090 |
Why?
|
Fluorescent Antibody Technique | 1 | 2010 | 314 | 0.090 |
Why?
|
Phylogeny | 2 | 2006 | 1136 | 0.090 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2010 | 199 | 0.090 |
Why?
|
Heat-Shock Proteins | 1 | 2010 | 178 | 0.090 |
Why?
|
RNA, Catalytic | 1 | 2010 | 129 | 0.090 |
Why?
|
Reoperation | 2 | 2006 | 589 | 0.090 |
Why?
|
Rats | 5 | 2008 | 3984 | 0.090 |
Why?
|
Leukocytes, Mononuclear | 1 | 2010 | 196 | 0.090 |
Why?
|
Lateral Ventricles | 1 | 2008 | 12 | 0.080 |
Why?
|
Surveys and Questionnaires | 1 | 2017 | 2495 | 0.080 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2010 | 302 | 0.080 |
Why?
|
Retinal Hemorrhage | 1 | 2008 | 9 | 0.080 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 877 | 0.080 |
Why?
|
NAD | 4 | 2013 | 65 | 0.080 |
Why?
|
Atrophy | 1 | 2008 | 117 | 0.080 |
Why?
|
Galactolipids | 1 | 2008 | 2 | 0.080 |
Why?
|
Choroidal Neovascularization | 1 | 2008 | 31 | 0.080 |
Why?
|
Neonatal Screening | 1 | 2009 | 59 | 0.080 |
Why?
|
Intracellular Space | 1 | 2008 | 38 | 0.080 |
Why?
|
Cricetulus | 1 | 2008 | 126 | 0.080 |
Why?
|
Microglia | 1 | 2008 | 102 | 0.080 |
Why?
|
CHO Cells | 1 | 2008 | 187 | 0.080 |
Why?
|
Models, Genetic | 2 | 2010 | 926 | 0.080 |
Why?
|
Protein Conformation | 3 | 2018 | 881 | 0.080 |
Why?
|
Epigenesis, Genetic | 2 | 2009 | 476 | 0.080 |
Why?
|
Plant Proteins | 2 | 2007 | 131 | 0.080 |
Why?
|
Protein Structure, Secondary | 1 | 2008 | 329 | 0.070 |
Why?
|
Macrophages | 1 | 2010 | 554 | 0.070 |
Why?
|
Retrospective Studies | 4 | 2006 | 8431 | 0.070 |
Why?
|
Ontario | 1 | 2006 | 52 | 0.070 |
Why?
|
Evidence-Based Medicine | 1 | 2009 | 429 | 0.070 |
Why?
|
Databases as Topic | 1 | 2006 | 92 | 0.070 |
Why?
|
Lipids | 1 | 2007 | 269 | 0.070 |
Why?
|
Polymorphism, Genetic | 1 | 2010 | 819 | 0.070 |
Why?
|
Eye Diseases | 2 | 2011 | 53 | 0.070 |
Why?
|
Folic Acid Antagonists | 1 | 2005 | 19 | 0.070 |
Why?
|
Anal Canal | 1 | 2006 | 89 | 0.070 |
Why?
|
Behavior, Animal | 1 | 2008 | 373 | 0.070 |
Why?
|
Eosinophilia | 1 | 2006 | 83 | 0.070 |
Why?
|
Nerve Tissue Proteins | 1 | 2008 | 503 | 0.070 |
Why?
|
Genome, Protozoan | 1 | 2005 | 10 | 0.070 |
Why?
|
T-Lymphocytes | 1 | 2011 | 1195 | 0.070 |
Why?
|
Rats, Sprague-Dawley | 1 | 2008 | 1214 | 0.060 |
Why?
|
Flow Cytometry | 2 | 2010 | 679 | 0.060 |
Why?
|
Gene Expression Profiling | 1 | 2010 | 1381 | 0.060 |
Why?
|
Regression Analysis | 1 | 2006 | 595 | 0.060 |
Why?
|
Species Specificity | 2 | 2007 | 678 | 0.060 |
Why?
|
Salicylamides | 1 | 2004 | 2 | 0.060 |
Why?
|
Oxyquinoline | 1 | 2004 | 4 | 0.060 |
Why?
|
Cognition Disorders | 1 | 2006 | 236 | 0.060 |
Why?
|
Permeability | 2 | 2015 | 133 | 0.060 |
Why?
|
DNA, Protozoan | 1 | 2003 | 16 | 0.060 |
Why?
|
Feasibility Studies | 1 | 2006 | 751 | 0.060 |
Why?
|
Mice, Knockout | 3 | 2015 | 1918 | 0.060 |
Why?
|
Leucovorin | 3 | 2008 | 218 | 0.060 |
Why?
|
DNA, Complementary | 2 | 1994 | 393 | 0.060 |
Why?
|
Quality of Life | 1 | 1991 | 1575 | 0.060 |
Why?
|
Radiography | 5 | 1997 | 812 | 0.060 |
Why?
|
Length of Stay | 1 | 2006 | 697 | 0.060 |
Why?
|
Transcription Factors | 1 | 2010 | 1555 | 0.060 |
Why?
|
Histocompatibility Antigen H-2D | 1 | 2002 | 5 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 2 | 2008 | 3347 | 0.050 |
Why?
|
Base Sequence | 3 | 1999 | 2329 | 0.050 |
Why?
|
Phosphorus-Oxygen Lyases | 1 | 2002 | 1 | 0.050 |
Why?
|
Time Factors | 4 | 2018 | 5198 | 0.050 |
Why?
|
Biomarkers | 1 | 2008 | 1709 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2008 | 1376 | 0.050 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2002 | 213 | 0.050 |
Why?
|
Crosses, Genetic | 1 | 2002 | 171 | 0.050 |
Why?
|
Aneuploidy | 1 | 2001 | 55 | 0.050 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2001 | 108 | 0.050 |
Why?
|
Twins, Dizygotic | 1 | 2021 | 40 | 0.050 |
Why?
|
Cognition | 1 | 2006 | 570 | 0.050 |
Why?
|
Prospective Studies | 4 | 2008 | 4194 | 0.050 |
Why?
|
Genetic Variation | 2 | 2014 | 1349 | 0.050 |
Why?
|
Delayed Diagnosis | 1 | 2021 | 29 | 0.050 |
Why?
|
RNA Interference | 2 | 2014 | 368 | 0.050 |
Why?
|
Kinetics | 2 | 2013 | 1513 | 0.050 |
Why?
|
HLA-A11 Antigen | 1 | 2020 | 2 | 0.050 |
Why?
|
Genome | 1 | 2004 | 371 | 0.050 |
Why?
|
Multigene Family | 1 | 2001 | 202 | 0.050 |
Why?
|
CD8 Antigens | 2 | 2010 | 82 | 0.050 |
Why?
|
Algorithms | 1 | 2009 | 1828 | 0.050 |
Why?
|
Incidental Findings | 1 | 2021 | 95 | 0.050 |
Why?
|
Evolution, Molecular | 1 | 2006 | 813 | 0.050 |
Why?
|
Parasitemia | 1 | 2000 | 6 | 0.050 |
Why?
|
Colonic Polyps | 1 | 2001 | 126 | 0.050 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2001 | 152 | 0.050 |
Why?
|
NG-Nitroarginine Methyl Ester | 1 | 2000 | 45 | 0.050 |
Why?
|
Herbicides | 1 | 1999 | 35 | 0.050 |
Why?
|
Signal Transduction | 1 | 2010 | 3233 | 0.050 |
Why?
|
Acetyl-CoA Carboxylase | 1 | 1999 | 24 | 0.050 |
Why?
|
Propionates | 1 | 1999 | 34 | 0.050 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2000 | 86 | 0.050 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 268 | 0.050 |
Why?
|
Vitreous Body | 2 | 2011 | 53 | 0.050 |
Why?
|
Protein Engineering | 1 | 2020 | 140 | 0.040 |
Why?
|
Restriction Mapping | 2 | 2002 | 157 | 0.040 |
Why?
|
Homozygote | 1 | 1999 | 200 | 0.040 |
Why?
|
Animals, Wild | 1 | 2019 | 40 | 0.040 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2001 | 380 | 0.040 |
Why?
|
France | 1 | 2018 | 47 | 0.040 |
Why?
|
Sex Factors | 1 | 2002 | 1053 | 0.040 |
Why?
|
Follow-Up Studies | 3 | 1995 | 3616 | 0.040 |
Why?
|
Actuarial Analysis | 1 | 1997 | 66 | 0.040 |
Why?
|
Survival Analysis | 1 | 2002 | 1536 | 0.040 |
Why?
|
Diagnosis, Differential | 2 | 2000 | 1562 | 0.040 |
Why?
|
Abortion, Spontaneous | 1 | 2018 | 66 | 0.040 |
Why?
|
Biopsy | 1 | 2001 | 1160 | 0.040 |
Why?
|
DNA Primers | 2 | 1999 | 542 | 0.040 |
Why?
|
Point-of-Care Systems | 1 | 2018 | 141 | 0.040 |
Why?
|
Farms | 1 | 2017 | 5 | 0.040 |
Why?
|
Massachusetts | 1 | 2017 | 33 | 0.040 |
Why?
|
Maryland | 1 | 2017 | 35 | 0.040 |
Why?
|
Ohio | 1 | 2017 | 36 | 0.040 |
Why?
|
Public Health | 1 | 2018 | 129 | 0.040 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 2017 | 147 | 0.040 |
Why?
|
Biological Assay | 1 | 2017 | 78 | 0.040 |
Why?
|
Tomography Scanners, X-Ray Computed | 1 | 1996 | 20 | 0.040 |
Why?
|
Developing Countries | 1 | 2017 | 69 | 0.040 |
Why?
|
Immunocompetence | 1 | 1996 | 27 | 0.040 |
Why?
|
Diagnostic Tests, Routine | 1 | 2017 | 62 | 0.040 |
Why?
|
Costs and Cost Analysis | 1 | 2017 | 153 | 0.040 |
Why?
|
Bone Cysts | 2 | 1992 | 10 | 0.040 |
Why?
|
Osteoma, Osteoid | 1 | 1976 | 9 | 0.040 |
Why?
|
Phthiraptera | 1 | 1995 | 1 | 0.030 |
Why?
|
Ticks | 1 | 1995 | 2 | 0.030 |
Why?
|
Parasitic Diseases | 1 | 1995 | 2 | 0.030 |
Why?
|
Mutation | 2 | 2002 | 3952 | 0.030 |
Why?
|
Methods | 1 | 1995 | 152 | 0.030 |
Why?
|
Genetic Markers | 1 | 2017 | 476 | 0.030 |
Why?
|
Infant, Newborn, Diseases | 1 | 1996 | 111 | 0.030 |
Why?
|
Ecosystem | 1 | 2019 | 315 | 0.030 |
Why?
|
Australia | 1 | 1995 | 99 | 0.030 |
Why?
|
Sheep | 1 | 1995 | 238 | 0.030 |
Why?
|
Mothers | 1 | 1996 | 140 | 0.030 |
Why?
|
Duodenum | 1 | 1995 | 99 | 0.030 |
Why?
|
Diptera | 1 | 1995 | 44 | 0.030 |
Why?
|
Integrin alpha Chains | 1 | 2015 | 14 | 0.030 |
Why?
|
Cattle | 1 | 1995 | 374 | 0.030 |
Why?
|
Occludin | 1 | 2015 | 63 | 0.030 |
Why?
|
Confidence Intervals | 1 | 1995 | 228 | 0.030 |
Why?
|
Pancreatitis | 1 | 1995 | 87 | 0.030 |
Why?
|
Transplantation Chimera | 1 | 2015 | 79 | 0.030 |
Why?
|
Mesalamine | 1 | 1995 | 88 | 0.030 |
Why?
|
X-Ray Diffraction | 2 | 2006 | 124 | 0.030 |
Why?
|
Mice, Inbred A | 1 | 1994 | 23 | 0.030 |
Why?
|
HLA-B27 Antigen | 1 | 1994 | 8 | 0.030 |
Why?
|
Caspase 1 | 1 | 2014 | 18 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2008 | 1015 | 0.030 |
Why?
|
HLA-C Antigens | 1 | 1994 | 21 | 0.030 |
Why?
|
Crystallization | 2 | 2006 | 206 | 0.030 |
Why?
|
HLA-D Antigens | 1 | 1994 | 20 | 0.030 |
Why?
|
Sulfur Radioisotopes | 1 | 1994 | 22 | 0.030 |
Why?
|
Apolipoprotein B-100 | 1 | 1994 | 12 | 0.030 |
Why?
|
Arachidonic Acid | 1 | 2014 | 63 | 0.030 |
Why?
|
Fibrous Dysplasia of Bone | 1 | 1993 | 1 | 0.030 |
Why?
|
Liver Neoplasms, Experimental | 1 | 1994 | 27 | 0.030 |
Why?
|
Bone Marrow Transplantation | 1 | 2015 | 285 | 0.030 |
Why?
|
Protein Unfolding | 1 | 2013 | 12 | 0.030 |
Why?
|
Heart | 1 | 2017 | 538 | 0.030 |
Why?
|
Patient Compliance | 1 | 1995 | 226 | 0.030 |
Why?
|
Temperature | 1 | 2015 | 395 | 0.030 |
Why?
|
Methionine | 1 | 1994 | 66 | 0.030 |
Why?
|
Molecular Conformation | 1 | 2013 | 96 | 0.030 |
Why?
|
Golgi Apparatus | 1 | 1994 | 117 | 0.030 |
Why?
|
Linkage Disequilibrium | 2 | 2008 | 473 | 0.030 |
Why?
|
Molecular Docking Simulation | 1 | 2013 | 46 | 0.030 |
Why?
|
Codon | 1 | 1994 | 124 | 0.030 |
Why?
|
Intestine, Small | 1 | 1995 | 303 | 0.030 |
Why?
|
Plasmids | 1 | 2014 | 287 | 0.030 |
Why?
|
High-Throughput Screening Assays | 1 | 2013 | 55 | 0.030 |
Why?
|
Caco-2 Cells | 1 | 2013 | 122 | 0.030 |
Why?
|
Hot Temperature | 1 | 2013 | 206 | 0.030 |
Why?
|
Antigens, CD | 1 | 2015 | 457 | 0.030 |
Why?
|
Cost-Benefit Analysis | 1 | 1995 | 450 | 0.030 |
Why?
|
Point Mutation | 1 | 1994 | 246 | 0.030 |
Why?
|
Lymph Nodes | 1 | 1996 | 530 | 0.030 |
Why?
|
Oxidation-Reduction | 1 | 2013 | 373 | 0.030 |
Why?
|
Host-Pathogen Interactions | 1 | 2015 | 230 | 0.030 |
Why?
|
Transfection | 1 | 1994 | 895 | 0.030 |
Why?
|
Prognosis | 1 | 2000 | 3669 | 0.030 |
Why?
|
Trypanosoma brucei rhodesiense | 1 | 2012 | 1 | 0.030 |
Why?
|
Trypanosoma cruzi | 1 | 2012 | 7 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2014 | 547 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 1994 | 1040 | 0.030 |
Why?
|
Th1 Cells | 1 | 2012 | 164 | 0.030 |
Why?
|
Immunoglobulin A | 1 | 2011 | 80 | 0.030 |
Why?
|
Combined Modality Therapy | 1 | 1995 | 1680 | 0.030 |
Why?
|
Uveitis, Anterior | 1 | 2011 | 5 | 0.030 |
Why?
|
Clinical Laboratory Techniques | 1 | 2011 | 73 | 0.030 |
Why?
|
Choroiditis | 1 | 2011 | 7 | 0.030 |
Why?
|
Bicarbonates | 2 | 1983 | 60 | 0.030 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2011 | 27 | 0.030 |
Why?
|
Swine Diseases | 1 | 2011 | 14 | 0.030 |
Why?
|
North America | 1 | 2011 | 179 | 0.020 |
Why?
|
Optic Nerve Diseases | 1 | 2011 | 18 | 0.020 |
Why?
|
Brazil | 1 | 2011 | 69 | 0.020 |
Why?
|
Meat | 1 | 2011 | 26 | 0.020 |
Why?
|
NLR Proteins | 1 | 2010 | 1 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 362 | 0.020 |
Why?
|
Double-Blind Method | 1 | 1995 | 1822 | 0.020 |
Why?
|
Osteosarcoma | 2 | 1986 | 158 | 0.020 |
Why?
|
Cicatrix | 1 | 2011 | 63 | 0.020 |
Why?
|
Postoperative Period | 1 | 1991 | 303 | 0.020 |
Why?
|
Receptors, Purinergic P2X7 | 1 | 2010 | 9 | 0.020 |
Why?
|
Cell Separation | 1 | 2010 | 196 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2000 | 6481 | 0.020 |
Why?
|
Cell Death | 1 | 2010 | 256 | 0.020 |
Why?
|
Swine | 1 | 2011 | 554 | 0.020 |
Why?
|
Oligopeptides | 1 | 2010 | 179 | 0.020 |
Why?
|
Preoperative Care | 1 | 1991 | 390 | 0.020 |
Why?
|
Ranibizumab | 1 | 2008 | 15 | 0.020 |
Why?
|
Genomic Imprinting | 1 | 2008 | 33 | 0.020 |
Why?
|
Injections | 1 | 2008 | 109 | 0.020 |
Why?
|
Microscopy, Immunoelectron | 1 | 2008 | 29 | 0.020 |
Why?
|
Tibia | 3 | 1993 | 82 | 0.020 |
Why?
|
Spinacia oleracea | 1 | 2008 | 15 | 0.020 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 1 | 2007 | 24 | 0.020 |
Why?
|
Fluorescein Angiography | 1 | 2008 | 96 | 0.020 |
Why?
|
Chloroplasts | 1 | 2008 | 68 | 0.020 |
Why?
|
Cataract Extraction | 1 | 2007 | 31 | 0.020 |
Why?
|
Eye | 1 | 2008 | 111 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2012 | 724 | 0.020 |
Why?
|
Tomography, Optical Coherence | 1 | 2008 | 130 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 1994 | 731 | 0.020 |
Why?
|
Apoenzymes | 1 | 2007 | 7 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2008 | 188 | 0.020 |
Why?
|
Amino Acids, Aromatic | 1 | 2006 | 3 | 0.020 |
Why?
|
Hydro-Lyases | 1 | 2006 | 6 | 0.020 |
Why?
|
Alcohol Oxidoreductases | 1 | 2006 | 17 | 0.020 |
Why?
|
Lyases | 1 | 2006 | 11 | 0.020 |
Why?
|
Transferases | 1 | 2006 | 24 | 0.020 |
Why?
|
Wechsler Scales | 1 | 2006 | 21 | 0.020 |
Why?
|
Rabbits | 1 | 2008 | 636 | 0.020 |
Why?
|
Prokaryotic Cells | 1 | 2006 | 15 | 0.020 |
Why?
|
Vision, Monocular | 1 | 2006 | 15 | 0.020 |
Why?
|
Intelligence Tests | 1 | 2006 | 38 | 0.020 |
Why?
|
Gene Transfer, Horizontal | 1 | 2006 | 34 | 0.020 |
Why?
|
Multienzyme Complexes | 1 | 2006 | 64 | 0.020 |
Why?
|
Language Tests | 1 | 2006 | 37 | 0.020 |
Why?
|
Gene Fusion | 1 | 2006 | 38 | 0.020 |
Why?
|
Macula Lutea | 1 | 2006 | 19 | 0.020 |
Why?
|
Vision, Binocular | 1 | 2006 | 20 | 0.020 |
Why?
|
Femoral Neoplasms | 1 | 1986 | 24 | 0.020 |
Why?
|
Eukaryotic Cells | 1 | 2006 | 43 | 0.020 |
Why?
|
Eukaryota | 1 | 2006 | 44 | 0.020 |
Why?
|
Computer Simulation | 1 | 2011 | 1077 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 1991 | 1610 | 0.020 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 2006 | 80 | 0.020 |
Why?
|
Fungi | 1 | 2006 | 65 | 0.020 |
Why?
|
Solvents | 1 | 2006 | 95 | 0.020 |
Why?
|
Periosteum | 1 | 1985 | 10 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 1992 | 1305 | 0.020 |
Why?
|
Chondroma | 1 | 1985 | 8 | 0.020 |
Why?
|
Antibodies | 1 | 2008 | 349 | 0.020 |
Why?
|
Plants | 1 | 2006 | 111 | 0.020 |
Why?
|
Symbiosis | 1 | 2006 | 118 | 0.020 |
Why?
|
Chondrosarcoma | 1 | 1985 | 48 | 0.020 |
Why?
|
Inflammation | 1 | 2011 | 913 | 0.020 |
Why?
|
Water | 1 | 2007 | 274 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 1986 | 318 | 0.020 |
Why?
|
Pattern Recognition, Visual | 1 | 2006 | 151 | 0.020 |
Why?
|
Cell Membrane | 1 | 2008 | 664 | 0.020 |
Why?
|
Actins | 1 | 2008 | 448 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 2 | 1986 | 2594 | 0.010 |
Why?
|
Mineralocorticoids | 1 | 1983 | 10 | 0.010 |
Why?
|
Ammonium Chloride | 1 | 1983 | 22 | 0.010 |
Why?
|
Maltose-Binding Proteins | 1 | 2003 | 31 | 0.010 |
Why?
|
Apoptosis | 1 | 2010 | 1678 | 0.010 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2008 | 929 | 0.010 |
Why?
|
Prenatal Care | 1 | 2003 | 72 | 0.010 |
Why?
|
Bacteria | 1 | 2006 | 445 | 0.010 |
Why?
|
Genes, Switch | 1 | 2002 | 8 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 2003 | 646 | 0.010 |
Why?
|
Host-Parasite Interactions | 1 | 2002 | 30 | 0.010 |
Why?
|
Gestational Age | 1 | 2003 | 310 | 0.010 |
Why?
|
Antigens, Surface | 1 | 2002 | 101 | 0.010 |
Why?
|
Hip Dislocation | 1 | 1981 | 10 | 0.010 |
Why?
|
Hip Dislocation, Congenital | 1 | 1981 | 13 | 0.010 |
Why?
|
Femur Neck | 1 | 1981 | 44 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2003 | 555 | 0.010 |
Why?
|
Glucocorticoids | 1 | 1983 | 347 | 0.010 |
Why?
|
Loop of Henle | 1 | 1979 | 12 | 0.010 |
Why?
|
Kidney Tubules | 1 | 1979 | 94 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 2001 | 1074 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2002 | 1135 | 0.010 |
Why?
|
Mandibular Neoplasms | 1 | 1976 | 24 | 0.010 |
Why?
|
Spinal Neoplasms | 1 | 1976 | 50 | 0.010 |
Why?
|
Femur | 1 | 1976 | 116 | 0.010 |
Why?
|
Extremities | 1 | 1976 | 165 | 0.010 |
Why?
|
Fibula | 1 | 1993 | 31 | 0.010 |
Why?
|
Humerus | 1 | 1986 | 31 | 0.000 |
Why?
|
Evaluation Studies as Topic | 1 | 1986 | 274 | 0.000 |
Why?
|
Pelvic Bones | 1 | 1986 | 44 | 0.000 |
Why?
|
Adrenalectomy | 1 | 1983 | 43 | 0.000 |
Why?
|
Rats, Inbred Strains | 1 | 1983 | 312 | 0.000 |
Why?
|
Enteral Nutrition | 1 | 1983 | 102 | 0.000 |
Why?
|
Water Deprivation | 1 | 1979 | 2 | 0.000 |
Why?
|
Kidney Tubules, Distal | 1 | 1979 | 20 | 0.000 |
Why?
|
Perfusion | 1 | 1979 | 202 | 0.000 |
Why?
|
Models, Biological | 1 | 1983 | 1748 | 0.000 |
Why?
|